[
  {
    "ts": "2026-01-27T04:35:19+00:00",
    "headline": "2 Profitable Stocks to Own for Decades and 1 Facing Headwinds",
    "summary": "Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.",
    "url": "https://finance.yahoo.com/news/2-profitable-stocks-own-decades-043519460.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "043bb5ef-7cd2-329c-8c23-7da6a6d0324e",
      "content": {
        "id": "043bb5ef-7cd2-329c-8c23-7da6a6d0324e",
        "contentType": "STORY",
        "title": "2 Profitable Stocks to Own for Decades and 1 Facing Headwinds",
        "description": "",
        "summary": "Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.",
        "pubDate": "2026-01-27T04:35:19Z",
        "displayTime": "2026-01-27T04:35:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/f4fa93632eac2e69a798f8bbc28c73ed",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "ELAN Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zGki2oQwdsi5AtPQ6WPOgw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/f4fa93632eac2e69a798f8bbc28c73ed.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8.iQjA71SyKK_Hvu6ml9xg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/f4fa93632eac2e69a798f8bbc28c73ed.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-profitable-stocks-own-decades-043519460.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-profitable-stocks-own-decades-043519460.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ELAN"
            },
            {
              "symbol": "EEFT"
            },
            {
              "symbol": "FOUR"
            },
            {
              "symbol": "FOUR-PA"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-27T13:38:52+00:00",
    "headline": "Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best US stocks to buy and hold in 2026. On January 20, Eli Lilly received FDA Breakthrough Therapy designation for sofetabart mipitecan. This status applies to the treatment of adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer whose disease has progressed despite prior therapies. […]",
    "url": "https://finance.yahoo.com/news/eli-lilly-lly-oncology-pipeline-133852697.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "2793d3c2-a111-3119-a03f-495f70d549b7",
      "content": {
        "id": "2793d3c2-a111-3119-a03f-495f70d549b7",
        "contentType": "STORY",
        "title": "Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best US stocks to buy and hold in 2026. On January 20, Eli Lilly received FDA Breakthrough Therapy designation for sofetabart mipitecan. This status applies to the treatment of adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer whose disease has progressed despite prior therapies. […]",
        "pubDate": "2026-01-27T13:38:52Z",
        "displayTime": "2026-01-27T13:38:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/101b148d88f043f017180ca8b31d9a4a",
          "originalWidth": 1920,
          "originalHeight": 1281,
          "caption": "Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/klOIJuPmSNUuqUttRqYcyw--~B/aD0xMjgxO3c9MTkyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/insidermonkey.com/101b148d88f043f017180ca8b31d9a4a.cf.webp",
              "width": 1920,
              "height": 1281,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NNO5eYVXOnUsR4MHY_ZoVg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/101b148d88f043f017180ca8b31d9a4a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-oncology-pipeline-133852697.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-lly-oncology-pipeline-133852697.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVDA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-27T14:27:00+00:00",
    "headline": "Where Will Eli Lilly Be in 10 Years?",
    "summary": "Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.",
    "url": "https://www.fool.com/investing/2026/01/27/where-will-eli-lilly-be-in-10-years/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "a092ab21-9d6f-30ed-a64a-f249470658b1",
      "content": {
        "id": "a092ab21-9d6f-30ed-a64a-f249470658b1",
        "contentType": "STORY",
        "title": "Where Will Eli Lilly Be in 10 Years?",
        "description": "",
        "summary": "Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.",
        "pubDate": "2026-01-27T14:27:00Z",
        "displayTime": "2026-01-27T14:27:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/682aed543fc56e09792bc6fbffaceaa2",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "A person using an injection pen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4b27HNps4qdSgIK0L7hHbA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/682aed543fc56e09792bc6fbffaceaa2.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/h8updXOQmOe001vEODVe8A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/682aed543fc56e09792bc6fbffaceaa2.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/27/where-will-eli-lilly-be-in-10-years/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/where-eli-lilly-10-years-142700298.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-27T14:00:05+00:00",
    "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-trending-140005558.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "021d7bd9-7da8-3f26-8b6e-bfc2f06479d7",
      "content": {
        "id": "021d7bd9-7da8-3f26-8b6e-bfc2f06479d7",
        "contentType": "STORY",
        "title": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
        "description": "",
        "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
        "pubDate": "2026-01-27T14:00:05Z",
        "displayTime": "2026-01-27T14:00:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee",
          "originalWidth": 900,
          "originalHeight": 876,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/H7_MbG.UY.XzK7FHlqhSdQ--~B/aD04NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee.cf.webp",
              "width": 900,
              "height": 876,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9cdhr7KlQi2r1salrGcJQg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-trending-140005558.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-company-lly-trending-140005558.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-27T16:22:00+00:00",
    "headline": "Up 36%, Is Eli Lilly Still a Buy?",
    "summary": "Thanks to its weight loss and diabetes products, the drug company has seen its shares soar.",
    "url": "https://www.fool.com/investing/2026/01/27/up-36-is-eli-lilly-still-a-buy/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "aff64f52-396c-3f29-96dc-654314d235e7",
      "content": {
        "id": "aff64f52-396c-3f29-96dc-654314d235e7",
        "contentType": "STORY",
        "title": "Up 36%, Is Eli Lilly Still a Buy?",
        "description": "",
        "summary": "Thanks to its weight loss and diabetes products, the drug company has seen its shares soar.",
        "pubDate": "2026-01-27T16:22:00Z",
        "displayTime": "2026-01-27T16:22:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/8bfd8819ba9c127e54acd14f9ab1f7e3",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Woman exercising in the woods. ",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Pi2W4ZqKGBk08mipcOxo9A--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/8bfd8819ba9c127e54acd14f9ab1f7e3.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_Cm_eWimxC.NIOOU6tjrcA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/8bfd8819ba9c127e54acd14f9ab1f7e3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/27/up-36-is-eli-lilly-still-a-buy/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/36-eli-lilly-still-buy-162200517.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-27T14:41:00+00:00",
    "headline": "Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?",
    "summary": "NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-vs-viking-obesity-144100886.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "5be3783a-d1b0-3ca2-8168-9b1072d72774",
      "content": {
        "id": "5be3783a-d1b0-3ca2-8168-9b1072d72774",
        "contentType": "STORY",
        "title": "Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?",
        "description": "",
        "summary": "NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.",
        "pubDate": "2026-01-27T14:41:00Z",
        "displayTime": "2026-01-27T14:41:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JLDGQt80ARh3qkafoo9TaA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ncdWYZW_rP_HUKWXjdodfA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/08c70fc44d9b8340859581d38311e071.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-vs-viking-obesity-144100886.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-vs-viking-obesity-144100886.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "VKTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-27T11:31:00+00:00",
    "headline": "Roche, trailing in obesity, showcases new data for GLP-1 shot",
    "summary": "A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.",
    "url": "https://www.biopharmadive.com/news/roche-obesity-drug-phase-2-data-carmot-glp-gip/810578/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "2963474c-e1de-3b97-9441-ab69674c65e1",
      "content": {
        "id": "2963474c-e1de-3b97-9441-ab69674c65e1",
        "contentType": "STORY",
        "title": "Roche, trailing in obesity, showcases new data for GLP-1 shot",
        "description": "",
        "summary": "A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.",
        "pubDate": "2026-01-27T11:31:00Z",
        "displayTime": "2026-01-27T11:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "BioPharma Dive, an Industry Dive publication",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/U3g5.ulK0vcCqcdyFlYvVw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DH6ljKWVk5FO27mUzvHUcQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/7bd263bcae7d0506fb80282303540fe7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/roche-obesity-drug-phase-2-data-carmot-glp-gip/810578/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/roche-trailing-obesity-showcases-data-113100723.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-27T18:00:00+00:00",
    "headline": "1 Pharmaceutical Stock Set to Rebound in 2026",
    "summary": "Novo Nordisk stock will ride a wave of demand for Ozempic pills in 2026.",
    "url": "https://www.fool.com/investing/2026/01/27/1-pharmaceutical-stock-set-to-rebound-in-2026/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "477a2d4d-fd33-33c7-8db1-6f3e26ac2479",
      "content": {
        "id": "477a2d4d-fd33-33c7-8db1-6f3e26ac2479",
        "contentType": "STORY",
        "title": "1 Pharmaceutical Stock Set to Rebound in 2026",
        "description": "",
        "summary": "Novo Nordisk stock will ride a wave of demand for Ozempic pills in 2026.",
        "pubDate": "2026-01-27T18:00:00Z",
        "displayTime": "2026-01-27T18:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/4fbffd1aef80cb43d29d5171e9f252d3",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "A patient injecting a GLP-1 into their arm.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_ZX6l8lZ1UqKyQN6_Rfq.A--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/4fbffd1aef80cb43d29d5171e9f252d3.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hLg25MqALpjImFvqY8zgnQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/4fbffd1aef80cb43d29d5171e9f252d3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/27/1-pharmaceutical-stock-set-to-rebound-in-2026/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-pharmaceutical-stock-set-rebound-180000004.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-27T19:35:30+00:00",
    "headline": "Roche Shares Rise After Obesity Drug Shows 18% Greater Weight Loss",
    "summary": "Mid-stage trial data showed Roche's experimental shot delivered weight loss on par with leading obesity treatments, supporting its late-stage trial plans.",
    "url": "https://finance.yahoo.com/news/roche-shares-rise-obesity-drug-193530744.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "62ace358-1e4f-3d39-a85b-6194287df70e",
      "content": {
        "id": "62ace358-1e4f-3d39-a85b-6194287df70e",
        "contentType": "STORY",
        "title": "Roche Shares Rise After Obesity Drug Shows 18% Greater Weight Loss",
        "description": "",
        "summary": "Mid-stage trial data showed Roche's experimental shot delivered weight loss on par with leading obesity treatments, supporting its late-stage trial plans.",
        "pubDate": "2026-01-27T19:35:30Z",
        "displayTime": "2026-01-27T19:35:30Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/ffc9542481f3ff2d9722cfd880ec25ef",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yTBkXNexAGsO8BgC_L7CFA--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/ffc9542481f3ff2d9722cfd880ec25ef.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Z8NVWpWDXNspu9jrf4giug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/ffc9542481f3ff2d9722cfd880ec25ef.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/roche-shares-rise-obesity-drug-193530744.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/roche-shares-rise-obesity-drug-193530744.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RHHBF"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "CRMO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]